



Solenio Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

May 17, 2022

REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Solenio Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL.

The presentation will be available on-demand beginning at 7 AM Eastern Time on Tuesday, May 24, 2022 in the Investors section on the Company's website at www.solenio.life.

About Solenio Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.solenio.life.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Solenio Therapeutics